Singapore markets close in 47 minutes

Singular Genomics Systems, Inc. (OMIC)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3720-0.0030 (-0.80%)
At close: 04:00PM EDT
0.3587 -0.01 (-3.58%)
After hours: 05:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3750
Open0.3730
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3569 - 0.3850
52-week range0.3100 - 1.0600
Volume107,889
Avg. volume121,158
Market cap27.563M
Beta (5Y monthly)1.43
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

    SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida. Singular Genomics’ management is scheduled to participate in a fireside chat Wednesday, June 12, 2024, at 7:40 a.m. Pacific Time / 10:40 a.m. Eastern Time. Inv

  • GlobeNewswire

    Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results

    SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024. “The first quarter was productive and encouraging. We are focused on supporting our existing customers and getting the G4X spatial sequencer to market

  • GlobeNewswire

    Singular Genomics to Report First Quarter 2024 Financial Results on May 14, 2024

    SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 14, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. East